Colin W G Fishwick

List of Publications by Year
in descending order

136 papers	4,799 citations	101384 36 h-index	118652 62 g-index
156 all docs	156 docs citations	156 times ranked	6568 citing authors

#	Article	IF	Citations
1	From Fragment to Lead: De Novo Design and Development toward a Selective FGFR2 Inhibitor. Journal of Medicinal Chemistry, 2022, 65, 1481-1504.	2.9	16
2	Recent developments in the structural characterisation of the IR and IGF1R: implications for the design of IRâ€“IGF1R hybrid receptor modulators. RSC Medicinal Chemistry, 2022, 13, 360-374.	1.7	12
3	Fibrinogen interaction with complement C3: a potential therapeutic target to reduce thrombosis risk. Haematologica, 2021, 106, 1616-1623.	1.7	9
4	Exploitation of a novel allosteric binding region in DNA gyrase and its implications for antibacterial drug discovery. Future Medicinal Chemistry, 2021, 13, 2125-2127.	1.1	4
5	Structure-Based Identification and Characterization of Inhibitors of the Epilepsy-Associated KNa1.1 (KCNT1) Potassium Channel. IScience, 2020, 23, 101100.	1.9	29
6	Bicyclic Boronates as Potent Inhibitors of AmpC, the Class C Î²-Lactamase from Escherichia coli. Biomolecules, 2020, 10, 899.	1.8	20
7	Potent Tetrahydroquinolone Eliminates Apicomplexan Parasites. Frontiers in Cellular and Infection Microbiology, 2020, 10, 203.	1.8	21
8	Discovery of Membrane-Bound Pyrophosphatase Inhibitors Derived from an Isoxazole Fragment. ACS Medicinal Chemistry Letters, 2020, 11, 605-610.	1.3	7
9	Structure-Guided Enhancement of Selectivity of Chemical Probe Inhibitors Targeting Bacterial Seryl-tRNA Synthetase. Journal of Medicinal Chemistry, 2019, 62, 9703-9717.	2.9	5
10	New insights into the binding mode of pyridine-3-carboxamide inhibitors of E. coli DNA gyrase. Bioorganic and Medicinal Chemistry, 2019, 27, 3546-3550.	1.4	39
11	Studies on the inhibition of AmpC and other Î²-lactamases by cyclic boronates. Biochimica Et Biophysica Acta - General Subjects, 2019, 1863, 742-748.	1.1	28
12	In Silico Fragment-Based Design Identifies Subfamily B1 Metallo-Î²-lactamase Inhibitors. Journal of Medicinal Chemistry, 2018, 61, 1255-1260.	2.9	40
13	Affimer proteins inhibit immune complex binding to FcÎ³RIIIa with high specificity through competitive and allosteric modes of action. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E72-E81.	3.3	36
14	CSGID Solves Structures and Identifies Phenotypes for Five Enzymes in Toxoplasma gondii. Frontiers in Cellular and Infection Microbiology, 2018, 8, 352.	1.8	14
15	Structure-switching M₃L₂ Ir(<scp>iii</scp>) coordination cages with photo-isomerising azo-aromatic linkers. Chemical Science, 2018, 9, 8150-8159.	3.7	69
16	Catalytic bimetalic [Pd(0)/Ag(I) Heck-1,3-dipolar cycloaddition cascade reactions accessing spiro-oxindoles. Concomitant in situ generation of azomethine ylides and dipolarophile. Tetrahedron, 2018, 74, 3564-3577.	1.0	13
17	X-ray and cryo-EM structures of inhibitor-bound cytochromebc₁complexes for structure-based drug discovery. IUCrJ, 2018, 5, 200-210.	1.0	23
18	Identification of a small molecule inhibitor of Ebola virus genome replication and transcription using in silico screening. Antiviral Research, 2018, 156, 46-54.	1.9	14

#	Article	IF	Citations
19	Cyclic Boronates Inhibit All Classes of Î²-Lactamases. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	94
20	A chemical genomics approach to drug reprofiling in oncology: Antipsychotic drug risperidone as a potential adenocarcinoma treatment. Cancer Letters, 2017, 393, 16-21.	3.2	31
21	Interconvertible geometric isomers of Plasmodium falciparum dihydroorotate dehydrogenase inhibitors exhibit multiple binding modes. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 3878-3882.	1.0	3
22	Tris-N-alkylpyridinium-functionalised cyclotriguaiacylene hosts as axles in branched [4]pseudorotaxane formation. Supramolecular Chemistry, 2017, 29, 430-440.	1.5	2
23	Structural/mechanistic insights into the efficacy of nonclassical Î²â€lactamase inhibitors against extensively drug resistant Stenotrophomonas maltophilia clinical isolates. Molecular Microbiology, 2017, 106, 492-504.	1.2	39
24	Inhibition of D-Ala:D-Ala ligase through a phosphorylated form of the antibiotic D-cycloserine. Nature Communications, 2017, 8, 1939.	5.8	59
25	Identification of an Indazole-Based Pharmacophore for the Inhibition of FGFR Kinases Using Fragment-Led de Novo Design. ACS Medicinal Chemistry Letters, 2017, 8, 1264-1268.	1.3	13
26	New paradigms for understanding and step changes in treating active and chronic, persistent apicomplexan infections. Scientific Reports, 2016, 6, 29179.	1.6	40
27	Natural and synthetic flavonoid modulation of TRPC5 channels. British Journal of Pharmacology, 2016, 173, 562-574.	2.7	42
28	Selective Phosphonylation of 5â€²-Adenosine Monophosphate (5â€²-AMP) via Pyrophosphite [PPi(III)]. Origins of Life and Evolution of Biospheres, 2016, 46, 425-434.	0.8	9
29	Structural basis of metallo-Î²-lactamase, serine-Î²-lactamase and penicillin-binding protein inhibition by cyclic boronates. Nature Communications, 2016, 7, 12406.	5.8	202
30	Î³-Carboline AC190 analogues via palladium catalysed allene insertion stereo and regioselective 3- and 5-component cascades. Tetrahedron, 2016, 72, 1316-1329.	1.0	8
31	A facile palladium catalysed 3-component cascade route to functionalised isoquinolinones and isoquinolines. Chemical Communications, 2016, 52, 164-166.	2.2	15
32	New Opportunities in the Structure-based Design of Anti-Protozoan Agents. Current Topics in Medicinal Chemistry, 2016, 17, 79-90.	1.0	7
33	(Â±) cis-bisamido epoxides: A novel series of potent FXIII-A inhibitors. European Journal of Medicinal Chemistry, 2015, 98, 49-53.	2.6	13
34	Identification of a lead like inhibitor of the hepatitis C virus non-structural NS2 autoprotease. Antiviral Research, 2015, 124, 54-60.	1.9	3
35	The First Small-Molecule Inhibitors of Members of the Ribonuclease E Family. Scientific Reports, 2015, 5, 8028.	1.6	25
36	Epoxide based inhibitors of the hepatitis C virus non-structural 2 autoprotease. Antiviral Research, 2015, 117, 20-26.	1.9	7

#	Article	IF	Citations
37	Inhibition of complement C3 and fibrinogen interaction: a potential novel therapeutic target to reduce cardiovascular disease in diabetes. Lancet, The, 2015, 385, S57.	6.3	19
38	Refining the chemical toolbox to be fit for educational and practical purpose for drug discovery in the 21st Century. Drug Discovery Today, 2015, 20, 1018-1026.	3.2	23
39	Computational Methods to Identify New Antibacterial Targets. Chemical Biology and Drug Design, 2015, 85, 22-29.	1.5	15
40	Identification of Receptor Tyrosine Kinase Inhibitors Using Cell Surface Biotinylation and Affinity Isolation. Methods in Molecular Biology, 2015, 1332, 121-131.	0.4	1
41	In Silico Design and Biological Evaluation of a Dual Specificity Kinase Inhibitor Targeting Cell Cycle Progression and Angiogenesis. PLoS ONE, 2014, 9, e110997.	1.1	12
42	An in silico structure-based approach to anti-infective drug discovery. Parasitology, 2014, 141, 17-27.	0.7	2
43	Cyclic dinucleotides bind the C-linker of HCN4 to control channel cAMP responsiveness. Nature Chemical Biology, 2014, 10, 457-462.	3.9	50
44	Encapsulation of sodium alkyl sulfates by the cyclotriveratrylene-based, [Pd₆L₈]¹²⁺ stella octangula cage. Dalton Transactions, 2014, 43, 5657-5661.	1.6	16
45	Discovery of novel FabF ligands inspired by platensimycin by integrating structure-based design with diversity-oriented synthetic accessibility. Organic and Biomolecular Chemistry, 2014, 12, 486-494.	1.5	25
46	Pyridine-3-carboxamide-6-yl-ureas as novel inhibitors of bacterial DNA gyrase: Structure based design, synthesis, SAR and antimicrobial activity. European Journal of Medicinal Chemistry, 2014, 86, 31-38.	2.6	45
47	Applications of structure-based design to antibacterial drug discovery. Bioorganic Chemistry, 2014, 55, 69-76.	2.0	18
48	Molecular mechanism of ligand recognition by membrane transport protein, Mhp1. EMBO Journal, 2014, 33, 1831-1844.	3.5	79
49	Adenosine Tetraphosphoadenosine Drives a Continuous ATP-Release Assay for Aminoacyl-tRNA Synthetases and Other Adenylate-Forming Enzymes. ACS Chemical Biology, 2013, 8, 2157-2163.	1.6	10
50	Assay Platform for Clinically Relevant Metallo-Î²-lactamases. Journal of Medicinal Chemistry, 2013, 56, 6945-6953.	2.9	100
51	The activation peptide cleft exposed by thrombin cleavage of FXIII-A2 contains a recognition site for the fibrinogen Î± chain. Blood, 2013, 121, 2117-2126.	0.6	31
52	Discovery of Biphenylacetamide-Derived Inhibitors of BACE1 Using de Novo Structure-Based Molecular Design. Journal of Medicinal Chemistry, 2013, 56, 1843-1852.	2.9	16
53	A Simple, One-Pot Synthesis of N-Alkyl and N-Aryl Thieno[2,3-d]pyrimidinones from Thiophene- and Benzothiophene-2-yl-ureas. Synthetic Communications, 2013, 43, 337-344.	1.1	2
54	A virtual high-throughput screening approach to the discovery of novel inhibitors of the bacterial leucine transporter, LeuT. Molecular Membrane Biology, 2013, 30, 184-194.	2.0	3

#	Article	IF	Citations
55	High-Risk Human Papillomavirus E5 Oncoprotein Displays Channel-Forming Activity Sensitive to Small-Molecule Inhibitors. Journal of Virology, 2012, 86, 5341-5351.	1.5	95
56	Factors Influencing the Specificity of Inhibitor Binding to the Human and Malaria Parasite Dihydroorotate Dehydrogenases. Journal of Medicinal Chemistry, 2012, 55, 5841-5850.	2.9	47
57	Identification of Selective Inhibitors of the Potassium Channel Kv1.1â€“1.2₍₃₎ by Highâ€Throughput Virtual Screening and Automated Patch Clamp. ChemMedChem, 2012, 7, 1775-1783.	1.6	20
58	Pregnenolone sulphate-independent inhibition of TRPM3 channels by progesterone. Cell Calcium, 2012, 51, 1-11.	1.1	72
59	Structure Guided Development of Potent Reversibly Binding Penicillin Binding Protein Inhibitors. ACS Medicinal Chemistry Letters, 2011, 2, 219-223.	1.3	28
60	Structure-Based Ligand Design of Novel Bacterial RNA Polymerase Inhibitors. ACS Medicinal Chemistry Letters, 2011, 2, 729-734.	1.3	17
61	XYâ€“ZH compounds as potential 1,3-dipoles. Part 65: atom economic cascade synthesis of highly functionalized pyrimidinylpyrrolidines. Tetrahedron, 2011, 67, 5700-5710.	1.0	13
62	Resistance mutations define specific antiviral effects for inhibitors of the hepatitis C virus p7 ion channel. Hepatology, 2011, 54, 79-90.	3.6	62
63	Activity of and Development of Resistance to Corallopyronin A, an Inhibitor of RNA Polymerase. Antimicrobial Agents and Chemotherapy, 2011, 55, 2413-2416.	1.4	28
64	A study of the effects of substituents on the selectivity of the binding of N-arylaminomethylene malonate inhibitors to DHODH. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 1284-1287.	1.0	17
65	Structure-based discovery of antibacterial drugs. Nature Reviews Microbiology, 2010, 8, 501-510.	13.6	122
66	Structureâ€based design of antiâ€infectives. Annals of the New York Academy of Sciences, 2010, 1213, 20-45.	1.8	21
67	Furanyl-Rhodanines Are Unattractive Drug Candidates for Development as Inhibitors of Bacterial RNA Polymerase. Antimicrobial Agents and Chemotherapy, 2010, 54, 4506-4509.	1.4	17
68	Benzothioxalone derivatives as novel inhibitors of UDP-N-acetylglucosamine enolpyruvyl transferases (MurA and MurZ). Journal of Antimicrobial Chemotherapy, 2010, 65, 2566-2573.	1.3	21
69	Analysis of mutational resistance to trimethoprim in Staphylococcus aureus by genetic and structural modelling techniques. Journal of Antimicrobial Chemotherapy, 2009, 63, 1112-1117.	1.3	38
70	Determinants of Hepatitis C Virus p7 Ion Channel Function and Drug Sensitivity Identified In Vitro. Journal of Virology, 2009, 83, 7970-7981.	1.5	62
71	The nature of Staphylococcus aureus MurA and MurZ and approaches for detection of peptidoglycan biosynthesis inhibitors. Molecular Microbiology, 2009, 72, 335-343.	1.2	75
72	Design and synthesis of new hydroxyethylamines as inhibitors of d-alanyl-d-lactate ligase (VanA) and d-alanyl-d-alanine ligase (DdlB). Bioorganic and Medicinal Chemistry Letters, 2009, 19, 1376-1379.	1.0	41

#	Article	IF	Citations
73	Discovery of novel non-peptide inhibitors of BACE-1 using virtual high-throughput screening. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 6770-6774.	1.0	28
74	Structure-Based Design, Synthesis, and Characterization of Inhibitors of Human and Plasmodium falciparum Dihydroorotate Dehydrogenases. Journal of Medicinal Chemistry, 2009, 52, 2683-2693.	2.9	84
75	2-Aminotetralones: Novel inhibitors of MurA and MurZ. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 1730-1734.	1.0	32
76	Synthesis of de novo designed small-molecule inhibitors of bacterial RNA polymerase. Tetrahedron, 2008, 64, 10049-10054.	1.0	23
77	Mutations in 15-hydroxyprostaglandin dehydrogenase cause primary hypertrophic osteoarthropathy. Nature Genetics, 2008, 40, 789-793.	9.4	267
78	Linezolid and Tiamulin Cross-Resistance in Staphylococcus aureus Mediated by Point Mutations in the Peptidyl Transferase Center. Antimicrobial Agents and Chemotherapy, 2008, 52, 1737-1742.	1.4	67
79	Design and Synthesis of Potent Inhibitors of the Malaria Parasite Dihydroorotate Dehydrogenase. Journal of Medicinal Chemistry, 2007, 50, 186-191.	2.9	60
80	Pd(0) catalyzed threeâ€“five-component C-2-arylallylation of active methylene heterocycles: pyrazolones, oxazolones, isoxazolones and N,Nâ€²-dimethylbarbituric acid. Tetrahedron, 2007, 63, 7213-7228.	1.0	13
81	Self-assembling Î²-Sheet Tape Forming Peptides. Supramolecular Chemistry, 2006, 18, 435-443.	1.5	80
82	Enantioselective synthesis of non-proteinogenic 2-arylallyl-Î±-amino acids via Pd/In catalytic cascades. Tetrahedron, 2006, 62, 12159-12171.	1.0	40
83	The first de novo designed inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 88-92.	1.0	69
84	Molecular Genetic and Structural Modeling Studies of Staphylococcus aureus RNA Polymerase and the Fitness of Rifampin Resistance Genotypes in Relation to Clinical Prevalence. Antimicrobial Agents and Chemotherapy, 2006, 50, 298-309.	1.4	111
85	Preparation of novel 3H-trifluoromethyldiazirine-based photoactivatable potassium channel antagonists. Tetrahedron, 2005, 61, 11244-11252.	1.0	6
86	Adsorption and Self-Assembly of Peptides on Mica Substrates. Angewandte Chemie - International Edition, 2005, 44, 1965-1968.	7.2	112
87	A De Novo Designed Inhibitor ofD-Ala-D-Ala Ligase fromE. coli. Angewandte Chemie - International Edition, 2005, 44, 6403-6406.	7.2	40
88	Stereoselective Palladium-Catalyzed Four-Component Cascade Synthesis of Pyrrolidinyl-, Pyrazolidinyl-, and Isoxazolidinyl Isoquinolines. Angewandte Chemie - International Edition, 2005, 44, 7570-7574.	7.2	57
89	The First de Novo-Designed Antagonists of the Human NK2Receptor. Journal of Medicinal Chemistry, 2005, 48, 5655-5658.	2.9	28
90	Analysis of Mupirocin Resistance and Fitness in Staphylococcus aureus by Molecular Genetic and Structural Modeling Techniques. Antimicrobial Agents and Chemotherapy, 2004, 48, 4366-4376.	1.4	77

#	Article	IF	Citations
91	1,3-Dipolar cycloaddition of stabilised and non-stabilised azomethine ylides derived from uracil polyoxin C (UPoC): access to nikkomycin analogues. Tetrahedron, 2004, 60, 3473-3485.	1.0	44
92	Three-Component Bimetallic (Pd/In) Mediated Cascade Allylation of C=X Functionality. Part 1. Scope and Class 1 Examples with Aldehydes and Ketones.. ChemInform, 2004, 35, no.	0.1	0
93	X=Yâ€“ZH system as potential 1,3-dipoles. Part 59: Cascade 1,3-azaprotio cyclotransferâ€“1,3-dipolar cycloaddition (1,3-APTâ€“1,3-DC) reactions of benzobicyclo[3.3.1]non-5-en-9-one oxime. Tetrahedron, 2003, 59, 9997-10007.	1.0	8
94	Three-component bimetallic (Pd/In) mediated cascade allylation of C=X functionality. Journal of Organometallic Chemistry, 2003, 687, 483-493.	0.8	22
95	Macrocyclic inhibitors of the bacterial cell wall biosynthesis enzyme mur D. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 1557-1560.	1.0	39
96	Structures of Helical Î²-Tapes and Twisted Ribbons:â€‰ The Role of Side-Chain Interactions on Twist and Bend Behavior. Nano Letters, 2003, 3, 1475-1479.	4.5	134
97	pH as a Trigger of Peptide Î²-Sheet Self-Assembly and Reversible Switching between Nematic and Isotropic Phases. Journal of the American Chemical Society, 2003, 125, 9619-9628.	6.6	441
98	The azomethine ylide strategy for Î²-lactam synthesis. A comprehensive mechanistic evaluation. Journal of the Chemical Society, Perkin Transactions 1, 2001, , 1270-1280.	1.3	7
99	The azomethine ylide strategy for Î²-lactam synthesis. An evaluation of alternative pathways for azomethine ylide generation. Journal of the Chemical Society, Perkin Transactions 1, 2001, , 1281-1289.	1.3	14
100	Spatial requirements of the antagonist binding site of the NK2 receptor. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 819-822.	1.0	13
101	RNA Polymerase Inhibitors with Activity against Rifampin-Resistant Mutants of Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 2000, 44, 3163-3166.	1.4	86
102	The synthesis and reactivity of optically pure amino acids bearing side-chain thioamides. Journal of the Chemical Society, Perkin Transactions 1, 2000, , 3227-3231.	1.3	12
103	Facile palladium catalysed functionalisation of 1,2-isothiazoline-3-ones and the highly diastereoselective Diels-Alder reactions of 4-vinyl-1,2-isothiazoline-3-one-1-oxides. Tetrahedron, 1999, 55, 12313-12330.	1.0	13
104	Generation and cycloadditions of 2-(N-acylamino)-1-thia-1,3-dienes part III: Control of diastereoselectivity using homochiral auxiliaries. Tetrahedron, 1998, 54, 3219-3234.	1.0	21
105	Novel synthesis of calamitic and discotic liquid crystalline derivatives of tetrathiafulvalene (TTF). Chemical Communications, 1998, , 113-114.	2.2	30
106	Two novel amino acid derivatives containing side-chain thioamides for the synthesis of photoactivatable peptides. Bioorganic and Medicinal Chemistry Letters, 1997, 7, 715-718.	1.0	6
107	Highly efficient diastereoselective Exo Diels-Alder reactions of homochiral 2-(N-acylamino)-1-thia-1,3-dienes: A powerful entry into optically pure thiopyrans. Tetrahedron Letters, 1996, 37, 123-126.	0.7	26
108	Hetero-1,3-dipolar cycloadditions of dithiolane-isocyanate imminium methylides: A novel route to 1,3-oxazolidine- and thiazolidine-2-thiones. Tetrahedron Letters, 1996, 37, 711-714.	0.7	15

#	Article	IF	Citations
109	A short dipolar cycloaddition approach to Î³-lactam alkaloids from cynometra hankei. Tetrahedron Letters, 1996, 37, 3915-3918.	0.7	48
110	Cyclic-fused azomethine-, imidate-, and thioimidate methylides: An efficient regiocontrolled entry into spiro-fused pyrrolidines. Tetrahedron Letters, 1996, 37, 5163-5166.	0.7	9
111	A Non-peptidic photoactivatable antagonist for mapping the antagonist binding site of the tachykinin NK2 receptor. Bioorganic and Medicinal Chemistry Letters, 1996, 6, 605-608.	1.0	4
112	Neighbouring group effects in a Pummerer-type rearrangement: A facile entry into 3,1-benzoxathiins. Tetrahedron, 1995, 51, 6819-6834.	1.0	10
113	Photoactivatable analogues of a Substance P non-peptidic antagonist, for probing the antagonist binding site of the NK1 receptor. Bioorganic and Medicinal Chemistry Letters, 1995, 5, 1271-1274.	1.0	7
114	Neighbouring group participation in Pummerer-type rearrangements of ortho-substituted arylmethyl sulphoxides. Tetrahedron Letters, 1995, 36, 2299-2302.	0.7	6
115	Remarkably high diastereoselective exo diels-alder reactivity of 4-vinyl isothiazoline-3-one-1-oxides: The sulphoxide Syn effect.. Tetrahedron Letters, 1995, 36, 7713-7716.	0.7	8
116	Dithiolane-isocyanate imminium methylides: A rapid stereoselective entry into Î³-lactams. Tetrahedron Letters, 1995, 36, 9409-9412.	0.7	18
117	The Preparation of a 3â€²-(2-Cyanoethyl)phosphoramidite of 5â€²-O-(3-Thiopropyl)methylphosphorylthymidine. Nucleosides & Nucleotides, 1995, 14, 1785-1794.	0.5	2
118	A Simple and Efficient Preparation of 3-Aryl-3-Trifluoromethyl-3H-Diazirinyl Sulfoxides and Sulfones. Synthesis, 1995, 1995, 553-556.	1.2	7
119	An efficient route to S-N-(9-fluorenylmethoxycarbonyl)-4â€²-(1-azi-2,2,2-trifluoroethyl)phenylalanine. Tetrahedron Letters, 1994, 35, 4611-4614.	0.7	35
120	Facile palladium catalysed functionalisation of 1,2-isothiazoline-3-ones. Tetrahedron Letters, 1994, 35, 6551-6554.	0.7	15
121	Hyperreactivity of adenines and conformational flexibility of a translational repression site. FEBS Letters, 1991, 283, 159-164.	1.3	9
122	Formation and mechanistic implication of a novel thiaazabicyclooctane derivative drug the cycloaddition of n-acetyl cinnamic acid thioamide. Tetrahedron Letters, 1991, 32, 2529-2532.	0.7	6
123	Facile intramolecular cycloadditions of 2-(N-Acylamino)-1-thia-1,3-dienes. Tetrahedron Letters, 1991, 32, 405-408.	0.7	17
124	A CONVENIENT PREPARATION OF ETHYL 3,3 DIMETHYL-3H-INDOLE-2-CARBOXYLATE. Organic Preparations and Procedures International, 1990, 22, 766-768.	0.6	3
125	Facile preparation of 2-imino tetrahydrofurans, pyrans and oxepans. Tetrahedron Letters, 1989, 30, 6571-6572.	0.7	15
126	Generation and cycloadditions of tetrahydrofuryl, pyranyl, and oxepanyl-2-imminium methylides. Tetrahedron Letters, 1989, 30, 6573-6576.	0.7	14

#	Article	IF	Citations
127	Preparation of methyl-2-(ï‰-iodoalkyl)propenoates and a facile route to 2-carbomethoxy-1,3-butadiene. Tetrahedron Letters, 1989, 30, 5653-5654.	0.7	5
128	Generation and cycloadditions of 2-(N-Acylamino)-1-thia-1,3-dienes. Part II. Rationalization of reactivity using an FMO approach.. Tetrahedron, 1989, 45, 7879-7898.	1.0	16
129	Generation and cycloadditions of 2-(N-acylamino)-1-thia-1, 3-dienes. Structural investigations using NMR methods. Part I.. Tetrahedron, 1989, 45, 6771-6790.	1.0	14
130	Detection and mechanistic implication of a dynamic equilibrium in some novel spiro-heterocyclic systems. Tetrahedron Letters, 1989, 30, 6777-6780.	0.7	5
131	Intramolecular [3+2] cycloadditions of non-stabilised azomethine imidate-methylides. Tetrahedron Letters, 1989, 30, 4443-4446.	0.7	14
132	Intramolecular [3+2] cycloaddition versus 1,4-hydrogen shift in indolium-N-methylides. Tetrahedron Letters, 1989, 30, 4447-4448.	0.7	11
133	Generation and cycloadditions of 2-(N-acylamino)-1-thia-1,3-dienes. Tetrahedron Letters, 1989, 30, 4449-4452.	0.7	18
134	[3+2] Cycloadditions of indolenine-derived azomethine ylides a rapid entry into pyrrolo [1,2-a] indolines.. Tetrahedron Letters, 1988, 29, 5325-5328.	0.7	17
135	A simple route to C-functionalised azaxylylenes and diazaxylylenes. Journal of the Chemical Society Chemical Communications, 1984, , 1304.	2.0	30
136	ortho-Quinonoid compounds. , 0, , 403-453.		8